Form D · Pharmaceuticals
Summit Biosciences Inc.
Lexington, KY · CIK 0001575898
Offering snapshot reported May 2, 2013 · SEC filing
- Reported sold
- Yet to sell Offering amount: $750K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 2, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-195907
Source: Form D, filed May 2, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Cohen | Director |
| Edwin A. Cohen | Director, Executive |
| Sonia L. Egbert | Executive |
| William Lomicka | Director |
| Charles Moyer | Director |
| Greg Plucinski | Executive |
| Robert Saunders | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1513 Bull Lea Road
Lexington, KY, 40511
Lexington, KY, 40511